The Patent Finder
US

Modified Release Formulations of a Bupropion Salt

US 7,241,805 Term ended
OverviewFamilyAssignmentsSources & methods
Collateral for a security interest recorded Nov 25, 2025 (JPMorgan Chase Bank, N.A.).

Term ended Jun 27, 2026 · High confidence

Filed Jun 27, 2006 as application 11/475,252 · Granted Jul 10, 2007
Base term, 20 years from filing
Today
20 years from filing
Term ended Jun 27, 2026
2006 2026
Clock starts
Jun 27, 2006
Term ended
Jun 27, 2026
Granted
Jul 10, 2007
base term after the term ends fee events Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
21
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.

This patent's term is its 20-year base term, with no adjustment for prosecution delay. All three maintenance fees were paid, so no fee lapse ended it. Confidence: High. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Jun 27, 2006, when this application, 11/475,252, was filedJun 27, 2026High confidence
Continuity chainEvery parent in the chain resolvedno changeHigh confidence
Patent term adjustmentNone on fileno changeHigh confidence
Terminal disclaimer capNone on recordno cap appliedHigh confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events3 of 3 maintenance fees paidterm endedHigh confidence
Computed term endThe steps above, in orderJun 27, 2026High confidence

Partial family

US 7,241,805this patent
Jun 2026
Jun 2026
US 7,569,610Term ended
Jun 2026
Jun 2026
US 7,563,823Term ended
Jun 2026
Jun 2026
US 7,553,992Term ended
no later than Jun 2026
no later than Jun 2026
US 7,649,019Term ended
no later than Jun 2026
no later than Jun 2026
US 8,932,628Term ended
no later than Sep 2026
no later than Sep 2026
Application 11/762,368Abandoned
not computed
not computed
US 7,569,611Term ended
Jun 2026
Jun 2026
8 of 21 applications in this family shown, earliest filings first. Partial: 2 of the 21 have no file history here, so a row comes from the patent's own record or names the application alone. The family may have others.

Assignments

The 40 most recent of 90 recorded documents are shown; the 50 earliest are not. Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
May 12, 2025
Reel 71088, frame 61
Valeant International BermudaValeant Holdings IrelandMerger
May 15, 2025
Reel 71124, frame 602
Valeant Holdings IrelandValeant Holdings Ireland, Luxembourg BranchMerger
May 15, 2025
Reel 71125, frame 884
Valeant Pharmaceuticals Ireland LimitedBausch Health Ireland LimitedChange of Name
May 15, 2025
Reel 71130, frame 894
Valeant Holdings Ireland, Luxembourg BranchValeant Pharmaceuticals Luxembourg S.À R.L.Assignment of Assignor's Interest
May 15, 2025
Reel 71291, frame 512
Valeant Pharmaceuticals Luxembourg S.À R.L.Valeant Pharmaceuticals IrelandAssignment of Assignor's Interest
Nov 20, 2025
Reel 73637, frame 1
The Bank of New York Mellon, as Notes Collateral AgentAton Pharma, Inc.; Bausch & Lomb Incorporated; Bausch & Lomb Pharma Holdings Corp.; Commonwealth Laboratories, LLC; Dow Pharmaceutical Sciences, Inc.; Ecr Pharmaceuticals Co., Inc.; Laboratoire Chauvin S.A.S.; Medicis Pharmaceutical Corporation; Onpharma Inc.; Orapharma, Inc.; Precision Dermatology, Inc.; Salix Pharmaceuticals, Ltd.; Salix Pharmaceuticals, Inc.; Santarus, Inc.; Solta Medical, Inc.; Synergetics USA, Inc.; Technolas Perfect Vision GmbH; Valeant Canada LP; Valeant Pharmaceuticals International; Valeant Pharmaceuticals International, Inc.; Valeant Pharmaceuticals North America LLC; Wirra IP Pty Limited; Valeant Pharma Poland SP. Z O.O.; Valeant Pharmaceuticals Luxembourg S.A R.L.; Valeant Pharmaceuticals Ireland LimitedRelease of Security Interest
Nov 20, 2025
Reel 73637, frame 222
The Bank of New York Mellon, as Notes Collateral AgentBausch Health Ireland Limited; Bausch Health Companies Inc.; Bausch Health, Canada Inc.; Technolas Perfect Vision GmbH; Valeant Pharmaceuticals Luxembourg S.A R.L.; Valeant Pharma Poland Spolka Z Organiczona Odpowiedzialnoscia; Valeant SP. Z.O.O.Release of Security Interest
Nov 20, 2025
Reel 73654, frame 300
The Bank of New York Mellon, as Notes Collateral AgentBausch Health Companies Inc.; Bausch Health, Canada Inc.; Bausch Health Ireland Limited; Solta Medical Ireland LimitedRelease of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentAton Pharma, Inc.Release of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentBausch & Lomb IncorporatedRelease of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentBausch & Lomb Pharma Holdings Corp.Release of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentCommonwealth Laboratories, LLCRelease of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentDow Pharmaceutical Sciences, Inc.Release of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentEcr Pharmaceuticals Co., Inc.Release of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentLaboratoire Chauvin S.A.S.Release of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentMedicis Pharmaceutical CorporationRelease of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentOnpharma Inc.Release of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentOrapharma, Inc.Release of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentPrecision Dermatology, Inc.Release of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentSalix Pharmaceuticals, Ltd.Release of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentSalix Pharmaceuticals, Inc.Release of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentSantarus, Inc.Release of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentSolta Medical, Inc.Release of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentSynergetics USA, Inc.Release of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentTechnolas Perfect Vision GmbHRelease of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentValeant Canada LPRelease of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentValeant Pharmaceuticals InternationalRelease of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentValeant Pharmaceuticals International, Inc.Release of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentValeant Pharmaceuticals North America LLCRelease of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentWirra IP Pty LimitedRelease of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentValeant Pharma Poland SP. Z O.O.Release of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentValeant Pharmaceuticals Luxembourg S.A R.L.Release of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentValeant Pharmaceuticals Ireland LimitedRelease of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentBausch Health Ireland LimitedRelease of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentBausch Health Companies Inc.Release of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentBausch Health, Canada Inc.Release of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentValeant Pharma Poland Spolka Z Organiczona OdpowiedzialnosciaRelease of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentValeant SP. Z.O.O.Release of Security Interest
Nov 20, 2025
reel/frame not recorded
The Bank of New York Mellon, as Notes Collateral AgentSolta Medical Ireland LimitedRelease of Security Interest
Nov 25, 2025
Reel 73715, frame 375
Bausch Health Ireland LimitedJpmorgan Chase Bank, N.a.U.S. Patent Security Agreement

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited